Clinical Trial Update: Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial of Cyclosporine Inhalation Solution (CIS) in lung transplant recipients completed, evaluating bronchiolitis obliterans syndrome-free survival.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome

Drugs mentioned

• Cyclosporine Inhalation Solution (CIS) (cyclosporine)

Snippet

Sponsor: APT Pharmaceuticals, Inc. | Conditions: Lung Transplant | Phase 3 | Status: COMPLETED